Compare SanBio Co., Ltd. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
JPY 152,077 Million ()
NA (Loss Making)
NA
0.00%
-1.24
-701.71%
308.98
Revenue and Profits:
Net Sales:
(Quarterly Results - Oct 2025)
Net Profit:
-717 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-34.23%
0%
-34.23%
6 Months
-25.69%
0%
-25.69%
1 Year
141.72%
0%
141.72%
2 Years
226.41%
0%
226.41%
3 Years
145.56%
0%
145.56%
4 Years
69.01%
0%
69.01%
5 Years
6.0%
0%
6.0%
SanBio Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
6.35%
EBIT to Interest (avg)
-111.21
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.43
Sales to Capital Employed (avg)
0
Tax Ratio
12.22%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
141.62
EV to EBIT
-70.29
EV to EBITDA
-70.48
EV to Capital Employed
-324.55
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-164.06%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Oct'25 - YoY
Oct'25
Oct'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-783.90
-908.50
13.71%
Interest
9.40
5.30
77.36%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-716.60
-843.20
15.01%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in quarter ended Oct 2025 is 0.00% vs 0.00% in Oct 2024
Consolidated Net Profit
YoY Growth in quarter ended Oct 2025 is 15.01% vs -782.93% in Oct 2024
Annual Results Snapshot (Consolidated) - Jan'25
Jan'25
Jan'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-3,506.70
-4,525.20
22.51%
Interest
18.90
25.80
-26.74%
Exceptional Items
9.30
252.30
-96.31%
Consolidate Net Profit
-2,882.90
-2,644.30
-9.02%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in year ended Jan 2025 is 0.00% vs 0.00% in Jan 2024
Consolidated Net Profit
YoY Growth in year ended Jan 2025 is -9.02% vs 52.44% in Jan 2024
About SanBio Co., Ltd. 
SanBio Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






